Molecular analysis of expressed TRB gene rearrangements further showed that the dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients were largely monoclonal, whereas the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients were either oligoclonal or polyclonal. Here, THRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.